Component
FF-20 fisetin micelle/fenugreek-galactomannan formulation
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
In a 15-person crossover study, 1000 mg FF-20 containing 192 mg fisetin produced a reported 26.9-fold higher 12-hour parent AUC than 1000 mg unformulated material.
Experimental context and source evidence
- evidence_access
- Primary full text
- experimental_model
- Single-dose healthy-volunteer study; 10-day washout; unformulated product contained approximately 982 mg fisetin.
- limitations
- Product-specific comparison, not demonstrated clinical superiority or a general effect of dietary fiber.
- nutrient_topic
- Fisetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Fisetin
- plain_language
- Formulation changed exposure despite less fisetin in the tested product.
- primary_references
- Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36304817/ · DOI 10.1017/jns.2022.72
Fisetin: metabolism, cell-state responses and cross-nutrient mechanisms (2026-09-19) · lines 72–78
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Single-dose healthy-volunteer study; 10-day washout; unformulated product contained approximately 982 mg fisetin. · source_derived_draft · unverified_draft
## fisetin-human-formulation Formulation changed exposure despite less fisetin in the tested product. In a 15-person crossover study, 1000 mg FF-20 containing 192 mg fisetin produced a reported 26.9-fold higher 12-hour parent AUC than 1000 mg unformulated material. Model: Single-dose healthy-volunteer study; 10-day washout; unformulated product contained approximately 982 mg fisetin. Limitations: Product-specific comparison, not demonstrated clinical superiority or a general effect of dietary fiber. Evidence access: Primary full text Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36304817/ · DOI 10.1017/jns.2022.72
Complete structured claim and evidence
Where it participates (unsigned role)
Geraldol was measured after oral fisetin in the human crossover study; its exposure relative to parent differed between formulations.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_access
- Primary abstract
- experimental_model
- Unconjugated parent and geraldol LC-MS/MS measurements.
- limitations
- Not a complete metabolite balance; altered ratios do not identify the causal absorption or metabolism step.
- nutrient_topic
- Fisetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Fisetin
- plain_language
- Human measurements confirm that parent exposure alone is incomplete.
- primary_references
- Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36304817/ · DOI 10.1017/jns.2022.72
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Fisetin: metabolism, cell-state responses and cross-nutrient mechanisms (2026-09-19) · lines 80–86
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Unconjugated parent and geraldol LC-MS/MS measurements. · source_derived_draft · unverified_draft
## fisetin-human-geraldol-exposure Human measurements confirm that parent exposure alone is incomplete. Geraldol was measured after oral fisetin in the human crossover study; its exposure relative to parent differed between formulations. Model: Unconjugated parent and geraldol LC-MS/MS measurements. Limitations: Not a complete metabolite balance; altered ratios do not identify the causal absorption or metabolism step. Evidence access: Primary abstract Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36304817/ · DOI 10.1017/jns.2022.72
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.